Advertisement

Picture Berlin Partner Top News CRIPSR Repairs Immune Cells 650x100px
Document › Details

Eckert & Ziegler AG. (9/25/23). "Press Release: Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma". Berlin.

Organisations Organisation Eckert & Ziegler, Wilmington, MA, manufacturing site
  Group Eckert & Ziegler (Group)
  Organisation 2 Point Biopharma Global Inc. (Nasdaq: PNT)
  Group Eli Lilly (Group)
Products Product lutetium-177 (medical isotope)
  Product 2 RADIOPHARMACEUTICAL (RPT)
Index terms Index term Point Biopharma–Eckert & Ziegler: radiopharmaceuticals, 202309–203309 supply 10y >$100m of nca lutetium-177 to Point Biopharma
  Index term 2 Point Biopharma–Lilly: investment, 202310–202312 cash tender offer $1.4b by Lilly at $12.5/share
Person Person Riehle, Karolin (Eckert & Ziegler 202212 Investor Relations + PR)
     


Insider information pursuant to Article 17 MAR


Eckert & Ziegler AG (ISIN DE0005659700, SDAX) today signed an agreement with POINT Biopharma Global Inc. ("POINT", NASDAQ: PNT) for the supply of carrier-free lutetium-177 (n.c.a.177Lu). The agreement has a term of ten years with a total sales volume of more than € 100 million.

The lutetium-177 supply is conditional to successful validation of Eckert & Ziegler-produced lutetium-177 with the intended compounds. POINT’s pipeline has multiple lutetium-177-based clinical candidates including one candidate for the treatment of metastatic castration-resistant prostate cancer. The agreement’s projected sales volume is based on the successful regulatory approval of a lutetium-177-based clinical candidate in the future.

To expand its manufacturing capacities, Eckert & Ziegler plans to invest around € 10 million in its own site in Wilmington, MA. Eckert & Ziegler is thus positioning itself as an important supplier of lutetium-177 in the rapidly growing radioligand therapy market.

The strategically significant agreement is expected to start contributing revenues in 2023 and generate substantial earnings if POINT's clinical candidates receive regulatory approval.

The lutetium-177 supply agreement follows a previously signed actinium-225 supply agreement between Eckert & Ziegler and POINT, announced on April 4, 2023.


Contact:

Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com


End of Inside Information

   
Record changed: 2024-01-20

Advertisement

Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for Eckert & Ziegler (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x300px




» top